Abstract
The Heat Shock Protein of 27 kDa (HSP27) is a molecular chaperone with anti-apoptotic properties and a role in cytoskeleton stability. Not surprisingly, HSP27 is often increased in cancers and associated with poor patients’ survival and resistance to conventional chemotherapy. Conversely, the role of HSP27 in response to therapies targeted towards oncogenic kinases was poorly characterized. In this chapter we review the findings on the role of HSP27 in resistance to both chemotherapeutics and targeted drugs and in the pro-metastatic phenotype, focusing on cancers where the tyrosine kinase receptor encoded by the MET oncogene is activated, namely, gastric and ovarian cancers. The inhibition of the MET receptor kinase in the MET addicted gastric cancer cells triggered HSP27 increase in a MEK/ERK dependent manner and in turn limited the effectiveness of inhibitors both in vitro and in vivo. Furthermore, in ovarian cancer cells HSP27 is required for metastasis upon MET activation in vivo and modulates the sensitivity to the first line chemotherapeutics Cisplatin and Paclitaxel. Altogether, these findings suggested that HSP27 induction by targeted agents might impact the success of targeted and conventional therapies and that it might be a suitable therapeutic target in combination treatments.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CDDP:
-
Cisplatin
- HGF/SF:
-
Hepatocyte growth factor/scatter factor
- HSP27:
-
Heat shock protein of 27 kDa
- PTX:
-
Paclitaxel
- RTK:
-
Receptor tyrosine kinase
- sHSP:
-
Small heat shock protein
References
Solimini NL, Luo J, Elledge SJ (2007) Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130:986–988
Conroy SE, Sasieni PD, Amin V, Wang DY, Smith P, Fentiman IS, Latchman DS (1998) Antibodies to heat-shock protein 27 are associated with improved survival in patients with breast cancer. Br J Cancer 77:1875–1879
Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kampinga HH, Van der Zee AG (1999) Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int J Cancer 84:234–238
Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS (2000) Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 60:7099–7105
Bruey JM, Paul C, Fromentin A, Hilpert S, Arrigo AP, Solary E, Garrido C (2000) Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 19:4855–4863
Zoubeidi A, Gleave M (2012) Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol 44:1646–1656
Pandey P, Farber R, Nakazawa A, Kumar S, Bharti A, Nalin C, Weichselbaum R, Kufe D, Kharbanda S (2000) Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene 19:1975–1981
Havasi A, Li Z, Wang Z, Martin JL, Botla V, Ruchalski K, Schwartz JH, Borkan SC (2008) Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism. J Biol Chem 283:12305–12313
Rane MJ, Pan Y, Singh S, Powell DW, Wu R, Cummins T, Chen Q, McLeish KR, Klein JB (2003) Heat shock protein 27 controls apoptosis by regulating Akt activation. J Biol Chem 278:27828–27835
Doshi BM, Hightower LE, Lee J (2009) The role of Hsp27 and actin in the regulation of movement in human cancer cells responding to heat shock. Cell Stress Chaperones 14:445–457
Wettstein G, Bellaye PS, Micheau O, Bonniaud P (2012) Small heat shock proteins and the cytoskeleton: an essential interplay for cell integrity? Int J Biochem Cell Biol 44:1680–1686
Torti D, Trusolino L (2011) Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med 3:623–636
Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11:834–848
Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L (2009) Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal 2:er11
Musiani D, Konda JD, Pavan S, Torchiaro E, Sassi F, Noghero A, Erriquez J, Perera T, Olivero M, Di Renzo MF (2014) Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy. FASEB J 28:4055–4067
Trusolino L, Comoglio PM (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2:289–300
Pavan S, Musiani D, Torchiaro E, Migliardi G, Gai M, Di Cunto F, Erriquez J, Olivero M, Di Renzo MF (2014) HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor. Int J Cancer 134:1289–1299
Baylot V, Andrieu C, Katsogiannou M, Taieb D, Garcia S, Giusiano S, Acunzo J, Iovanna J, Gleave M, Garrido C, Rocchi P (2011) OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis 2:e221
Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M (2007) Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 67:10455–10465
Gibert B, Hadchity E, Czekalla A, Aloy MT, Colas P, Rodriguez-Lafrasse C, Arrigo AP, Diaz-Latoud C (2011) Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers. Oncogene 30:3672–3681
Acknowledgments
The Authors thank Prof. Ferdinando Di Cunto, Dr. Marta Gai, Dr. Giorgia Migliardi, Dr. Alessio Noghero, Dr. Timothy Perera, Dr. Luca Cirillo and Dr. Francesco Sassi for the contribution to the original articles. The original work has been supported by grants to M.F.D.: 2012 IG Grant n°13050 and 2010 Special Program Molecular Clinical Oncology 5xMille of the Italian Association of Cancer Research (AIRC), Project n° 9970, grant of the CARIPLO Foundation and grant of the Progetto di Ateneo- Compagnia di San Paolo n° ORTO11RKTW.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Musiani, D. et al. (2015). Heat Shock Protein 27 (HSP27, HSPB1) Is Up-Regulated by Targeted Agents and Confers Resistance to Both Targeted Drugs and Chemotherapeutics. In: Asea, A., Almasoud, N., Krishnan, S., Kaur, P. (eds) Heat Shock Protein-Based Therapies. Heat Shock Proteins, vol 9. Springer, Cham. https://doi.org/10.1007/978-3-319-17211-8_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-17211-8_2
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-17210-1
Online ISBN: 978-3-319-17211-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)